The Lyon & Illkirch Graffenstaden-based company has raised €2.1m in its first round of financing and is a clinical stage immuno-oncology company that creates innovative therapeutic antibodies that target tumors and their immune and/or vascular microenvironment. ElsaLys Biotech's antibodies are designed to be more effective and safer than traditional treatments, and the company is committed to advancing the fight against cancer.